About Us

IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company’s AI process to provide healthcare professionals with decision support in the detection and monitoring of various disease conditions.

PressureSafe, the company’s first product based on this platform, is a handheld device designed to revolutionize early detection of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually.  PressureSafe is expected to contribute to early detection of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI.

IR-MED holds patents protecting its innovation in noninvasive tissue analysis and in modeling and analysis of subcutaneous tissue.

Oded Bashan

Chairman

Ronnie Klein

CTO and interim CEO

Aharon Binur

Chief Development Officer

Sharon Levkoviz

Chief Financial Officer

Avi Vachnis

Head of Software & AI

Yoram-Drucker

Yoram Drucker

VP Business Development

Awards

Most Innovative Non-Invasive Diagnostics Technology Developer 2023 - Israel

This revolutionary device, known as PressureSafe™, uses infrared spectroscopy and AI based analysis technology to power point-of-care decision support. Bio-healthcare information is non-invasively gathered from patient blood and tissue to help detect and monitor various disease conditions. 

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.